| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.083 | 0.008 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.008 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.008 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |